Streetbeat News

Stock Prices

APP

CCSI

DAKT

FORM

RXT

Five tech stocks are identified as overbought based on their RSI values, indicating potential short-term declines. Rackspace Technology, Daktronics, Consensus Cloud Solutions, AppLovin Corporation, and FormFactor have shown significant price gains recently, but their high RSI readings suggest they may face downward pressure.

Portfolio Pulse from Avi Kapoor

May 13, 2024 | 12:45 pm

OKLO

Oklo shares have seen increased trading activity and volatility following its business combination with AltC Acquisition Corp. and its recent debut on the NYSE. Additionally, Oklo announced a memorandum of understanding (MOU) with Atomic Alchemy to collaborate on isotope production.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:42 pm

ACIU

GME

TVGN

GameStop, AC Immune, and Tevogen Bio Holdings saw significant stock price movements due to various factors. GME rose amid retail investor interest sparked by Roaring Kitty. ACIU surged after Q1 financial results and a deal with Takeda for Alzheimer's treatment. TVGN climbed following a financing agreement for up to $50 million.

Portfolio Pulse from ryanfaloona@benzinga.com

May 13, 2024 | 12:42 pm

RNAZ

TransCode Therapeutics has issued an open letter to shareholders regarding a proposed reverse stock split to maintain its Nasdaq listing. The company's stock failed to meet the Nasdaq's Minimum Bid Requirement by not closing at $1.00 or more for any ten-day period ended May 6. Nasdaq has recommended delisting, but TransCode plans to appeal this decision at a Nasdaq Panel Hearing. The reverse split is considered a last resort to remain listed, and the company's stock has recently closed above $1.00 for four consecutive days.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:41 pm

TYRA

Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Tyra Biosciences (NASDAQ:TYRA) and increased the price target from $25 to $28.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:38 pm

ATNM

Actinium Pharmaceuticals, Inc. (ATNM) announced that five abstracts related to its targeted radiotherapies, Iomab-B and Actimab-A, for acute myeloid leukemia (AML) have been accepted for presentation at the 2024 SNMMI Annual Meeting. These therapies have shown improved survival rates in high-risk AML patients, including those with TP53 mutations and prior venetoclax treatment. Additionally, Actinium's novel linker technology is expanding its Antibody Radiation Conjugate pipeline into solid tumor indications.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:38 pm

LIVE

Live Ventures reported Q2 2024 earnings with a GAAP EPS of $(1.04), missing the $1.50 estimate, while sales of $118.626M exceeded the $105.000M estimate, marking a 30.18% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:33 pm

CIM

FTRE

SRG

VTS

Seritage Growth Properties reported a Q1 loss, leading to a significant drop in its pre-market stock price. Other companies like Vitesse Energy, Chimera Investment, Fortrea Holdings, and several others also experienced declines in pre-market trading due to various reasons including disappointing earnings, reverse stock splits, and downgrades by analysts.

Portfolio Pulse from Avi Kapoor

May 13, 2024 | 12:31 pm

AGS

AMAT

BHVN

CRH

CROX

DCBO

EYPT

MTD

PENN

RPD

Wall Street analysts have updated their price targets and ratings for several US-listed companies, leading to various stock price movements. Notable changes include downgrades for Applied Materials and PENN Entertainment, and upgrades for Mettler-Toledo and Crocs, among others.

Portfolio Pulse from Avi Kapoor

May 13, 2024 | 12:31 pm

ZEEKR Intelligent shares are experiencing an increase in their trading value due to post-IPO volatility.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:31 pm